Home

The Korea Herald

Latest news

Most Popular

  1. 1

    Contentious grain bill put directly to plenary meeting for vote

    Contentious grain bill put directly to plenary meeting for vote
  2. 2

    Yoon's approval rating plunges to all-time low

    Yoon's approval rating plunges to all-time low
  3. 3

    Will tug-of-war between doctors, government end soon?

    Will tug-of-war between doctors, government end soon?
  4. 4

    Climate impacts set to cut 2050 global GDP by nearly a fifth

    Climate impacts set to cut 2050 global GDP by nearly a fifth
  5. 5

    Trilateral talks acknowledge ‘serious’ slumps of won, yen

    Trilateral talks acknowledge ‘serious’ slumps of won, yen
  1. 6

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs

    [KH Explains] Hyundai's full hybrid edge to pay off amid slow transition to pure EVs
  2. 7

    North Korea removes streetlights along cross-border roads with South

    North Korea removes streetlights along cross-border roads with South
  3. 8

    Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official

    Russia's denial of entry of S. Korean national unrelated to bilateral ties: Seoul official
  4. 9

    S. Korea votes in favor of Palestinian bid for UN membership

    S. Korea votes in favor of Palestinian bid for UN membership
  5. 10

    Farming households dip below 1m for first time in 2023

    Farming households dip below 1m for first time in 2023
피터빈트

Regulator to conduct special audit on Samsung BioLogics

By KH디지털2

Published : March 30, 2017 - 15:31

    • Link copied

South Korea's financial regulator said Thursday that it will conduct a special audit on Samsung BioLogics Co., a biopharmaceutical unit of Samsung Group, over alleged accounting irregularities.

The Financial Supervisory Service made the decision on Wednesday, an FSS official said. 

(Yonhap) (Yonhap)

The FSS official, who spoke on the condition of anonymity, said the regulator found "unclear parts" in an audit report of Samsung BioLogics, which was revised by the Korean Institute of Certified Public Accountants.

The audit report was published before an initial public offering by Samsung Biologics last November.

Samsung BioLogics had been suffering losses since 2011, but reported a net profit of 1.9 trillion won ($1.7 billion) in 2015.

Samsung BioLogics said it has yet to receive a notification from the FSS, but it will cooperate with a special audit to clear up "factual grounds." (Yonhap)

More from Headlines